Welcome to our dedicated page for Bio-Path Hldgs SEC filings (Ticker: BPTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bio-Path Holdings filings document a clinical-stage biotechnology issuer focused on DNAbilize® liposomal delivery and antisense RNAi nanoparticle drug candidates. Material-event reports, exchange notices and late-filing notifications address governance, operating continuity, financing and capital-structure disclosures, and the common stock's registration or trading status.
The company's recent filings also record corporate-status and governance matters, including Nasdaq removal from listing, OTC Pink common stock disclosure, Wyoming domestication, creation of Series S Preferred stock, board and executive changes, a late Form 10-Q notification, and an operational pause instituted to conserve capital.
Bio-Path Holdings disclosed several strategic changes and capital-related steps. The company issued a shareholder update announcing a growth-focused repositioning, brought on new scientific advisors, engaged advisors to connect with strategic and financial investors, and canceled a previously approved 1-for-30 reverse stock split.
The Board approved a “digital asset treasury 2.0” program using AI to trade and accumulate multiple L1 and L2 blockchains and authorized opening an account with Coinbase or similar exchanges to buy, sell, and hold cryptocurrencies acquired through various channels. The Board also approved assigning to the company up to $10,000,000 of a $57,903,750 judgment, plus stated interest amounts, previously awarded to CEO Vikram Grover, with consideration to be paid in company securities when the judgment is monetized, aiming for accretion to shareholders. The company cautions there is no assurance Mr. Grover will obtain custodianship needed to complete related transactions.
Bio-Path Holdings reports a sharply reduced first-quarter loss but remains in severe financial distress. For the three months ended March 31, 2026, operating expenses fell to $0.3 million from $3.2 million a year earlier as research and development dropped to $0.04 million and general and administrative to $0.3 million, reflecting an operational pause and furloughs. Net loss narrowed to $0.3 million, or $0.03 per share, versus $2.9 million, or $0.40 per share, in the prior-year quarter.
Total assets were only $0.7 million against $9.2 million of liabilities, leaving shareholders’ deficit at $8.5 million. The company discloses that approximately $0.1 million of cash at March 31, 2026 is not enough to fund the next 12 months and states that substantial doubt exists about its ability to continue as a going concern. Several short-term promissory notes are already in default and carry default repayment at 150% of principal plus 22% default interest, with deep-discount conversion rights into common stock.
The report also notes that the March 31, 2026 financial statements are unaudited and have not been reviewed by an independent registered public accounting firm, so the filing is considered deficient. Subsequent to quarter-end, Bio-Path raised small amounts of equity under a Tier 1 Regulation A offering and issued 40 million common shares to Steel Giants Advisors LLC for accrued consulting compensation and wages due to the CEO, massively increasing the share count from 9.3 million at March 31, 2026 to over 50 million shares outstanding by May 20, 2026, and significantly diluting existing holders.
Bio-Path Holdings, Inc. filed a Form 12b-25 notifying the SEC that its Form 10-Q for the period ended March 31, 2026 will be late while it compiles information for the year ended December 31, 2025. The notification is signed by Vikram Grover and dated May 15, 2026.
Bio-Path Holdings, Inc. reported several corporate updates. The company’s domestication to Wyoming was approved by the Wyoming Secretary of State on March 5, 2026, and it filed an amendment creating a new Series S Preferred Stock class with 51 authorized shares, each convertible into one common share and carrying 1% of the company’s diluted voting power.
Effective February 10, 2026, Bio-Path appointed Wendy M. Charles, PhD and Michael Hickey to its newly formed Scientific Advisory Board. Both entered three-year advisory agreements and each received 100,000 stock options with a $0.06 exercise price and a three-year expiration, subject to adjustment.
Bio-Path Holdings, Inc. reported several governance and strategic actions, including issuing Steel Giants Advisors LLC 51 shares of new Series S Preferred stock and 2,000,000 common stock purchase warrants in exchange for $10,000 of accrued payables. The company filed to domesticate from Delaware to Wyoming, expecting approval in March 2026, and is negotiating with creditors while evaluating restarting certain Phase 1 and Phase 2 drug trials. Bio-Path engaged Farrington Capital Group for technology and strategic support, paying $1,000 and issuing 100,000 restricted common shares, created a Strategic Advisory Board with associated option incentives, and, together with its majority holder, canceled a previously approved 1-for-30 reverse stock split, concluding it was not in shareholders’ interests.
Bio-Path Holdings, Inc. reports a third-quarter 2025 net loss of $1.0 million, narrower than the prior-year quarter, as operating expenses fell sharply after the company paused most activities. For the nine months ended September 30, 2025, the net loss was $8.4 million.
Cash fell to $0.0 million at September 30, 2025, with total assets of $0.7 million against current liabilities of $8.7 million, resulting in shareholders’ deficit equity of $(8.0) million. Management states that available cash will not fund the next 12 months, and explicitly concludes that substantial doubt exists about the company’s ability to continue as a going concern.
The company has furloughed most employees and instituted a company‑wide operational pause to conserve capital, while relying on dilutive financings and high‑cost promissory notes that carry default penalties and conversion features. Notes issued in March 2025 are already in default and an April 2025 note defaulted after quarter end, creating a derivative liability of $0.3 million. Subsequent events include appointment of a new CEO/CFO, engagement of a restructuring advisor granted inexpensive warrants and majority voting power via new Series S preferred shares, and additional small promissory notes in January 2026.